PRIME study: Aducanumab in Alzheimer’s disease

Clinical trial (Phase I) designed to evaluate the safety and tolerability of multiple doses of Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb) in participants with prodromal or mild Alzheimer's Disease (AD).